MedDataX Logo

Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction

NCT ID: NCT01073514

Last Updated: 2015-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-12-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate bile culture and susceptibility test in patients with malignant biliary obstruction (MBO) or relation between bile, portal vein or vein culture and biliary infection. Also to get the information of bile metabonomics to find potential tumor marker .Culture of the organism is recognized as the "gold standard" for diagnosis of infection. Our research may be one of the first research on culture and susceptibility test in patients with MBO. The results of the trial research will be benefit to experiential therapy of MBO with biliary infection and diagnosis of MBO.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will obtain bile sample for culture and susceptibility ,proteomics metabonomics test after PTBD. Also get the blood and urine samples.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Biliary Obstruction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Malignant biliary obstruction (MBO)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Those with MBO who can receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Exclusion Criteria

* Those with MBO who cannot receive Percutaneous Transhepatic Biliary Drainage(PTBD)
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

YU HAI PENG, MD

Role: PRINCIPAL_INVESTIGATOR

Tianjin Medical University Cancer Institute and Hospital

GUO ZHI, Professor

Role: STUDY_CHAIR

Tianjin Medical University Cancer Institute and Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tianjin Medical University Cancer Institude and Hospital

Tianjin, Tianjin Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

YU HAI PENG, MD

Role: CONTACT

Phone: 13352070835

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

YU HAIPENG, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ChiCTR-ONC-00000752

Identifier Type: REGISTRY

Identifier Source: secondary_id

TMU-CIH-IR-001

Identifier Type: -

Identifier Source: org_study_id